Ozempic vs Mounjaro
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Ozempic | US Mounjaro | |
|---|---|---|
| Generic name | semaglutide | tirzepatide |
| Drug class | GLP-1 Receptor Agonist | GIP/GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Year approved | 2017 | 2022 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $420M | $350M |
| Common side effects | Nausea, Vomiting, Diarrhea, Abdominal pain | Nausea, Diarrhea, Decreased appetite, Vomiting |
Frequently asked questions
Is Ozempic or Mounjaro better?
Neither is universally "better." Ozempic (semaglutide) and Mounjaro (tirzepatide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ozempic and Mounjaro?
Ozempic is a GLP-1 Receptor Agonist made by Novo Nordisk, while Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ozempic has the larger estimated TV advertising budget of the two.